Daily Stock Analysis, FLXN, Flexion Therapeutics Inc, priceseries

Flexion Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
16.27
Close
16.50
High
16.76
Low
16.27
Previous Close
16.44
Daily Price Gain
0.06
YTD High
17.82
YTD High Date
Nov 4, 2019
YTD Low
8.76
YTD Low Date
Aug 5, 2019
YTD Price Change
4.04
YTD Gain
32.42%
52 Week High
17.82
52 Week High Date
Nov 4, 2019
52 Week Low
8.76
52 Week Low Date
Aug 5, 2019
52 Week Price Change
0.51
52 Week Gain
3.19%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
17.79
Jul 31. 2017
23.29
29 Trading Days
30.91%
Link
LONG
Aug 22. 2017
22.89
Sep 1. 2017
24.26
8 Trading Days
5.97%
Link
LONG
May 9. 2019
11.55
May 28. 2019
12.53
12 Trading Days
8.46%
Link
LONG
Aug 23. 2019
11.07
Sep 26. 2019
14.39
23 Trading Days
29.96%
Link
LONG
Oct 23. 2019
15.19
Nov 8. 2019
16.24
12 Trading Days
6.89%
Link
Company Information
Stock Symbol
FLXN
Exchange
NasdaqGM
Company URL
http://www.flexiontherapeutics.com
Company Phone
(781) 305-7777
CEO
Michael D. Clayman
Headquarters
Massachusetts
Business Address
10 MALL ROAD, SUITE 301, BURLINGTON, MA 01803
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001419600
About

Flexion Therapeutics, Inc. is a pharmaceutical company focuses on development and commercialization of novel, local therapies. It specializes in treatment of patients with musculoskeletal conditions including osteoarthritis, a type of degenerative arthritis. Its products include Zilretta. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Description

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.